1. Home
  2. MCB vs NTLA Comparison

MCB vs NTLA Comparison

Compare MCB & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metropolitan Bank Holding Corp.

MCB

Metropolitan Bank Holding Corp.

HOLD

Current Price

$81.97

Market Cap

833.3M

Sector

Finance

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$8.84

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCB
NTLA
Founded
1999
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
833.3M
986.9M
IPO Year
2017
2016

Fundamental Metrics

Financial Performance
Metric
MCB
NTLA
Price
$81.97
$8.84
Analyst Decision
Buy
Buy
Analyst Count
1
22
Target Price
$90.00
$19.83
AVG Volume (30 Days)
81.3K
4.0M
Earning Date
01-22-2026
11-06-2025
Dividend Yield
0.74%
N/A
EPS Growth
8.50
N/A
EPS
5.80
N/A
Revenue
$261,456,000.00
$57,528,000.00
Revenue This Year
$15.57
$1.96
Revenue Next Year
$13.99
N/A
P/E Ratio
$13.94
N/A
Revenue Growth
1.27
33.52
52 Week Low
$47.08
$5.90
52 Week High
$82.45
$28.25

Technical Indicators

Market Signals
Indicator
MCB
NTLA
Relative Strength Index (RSI) 73.65 40.31
Support Level $79.08 $8.90
Resistance Level $82.45 $9.55
Average True Range (ATR) 2.73 0.55
MACD 0.35 0.29
Stochastic Oscillator 95.07 45.84

Price Performance

Historical Comparison
MCB
NTLA

About MCB Metropolitan Bank Holding Corp.

Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: